Introduction
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, accounting for the death of one in three people each year. [1, 2] Of the 17.3 million deaths per year due to CVD, coronary artery disease (CAD) was responsible for over 40% of cases. [2] Current treatment modalities for CAD include percutaneous coronary intervention (PCI) with balloon angioplasty and stent implantation. However, despite advances in stent technology (e.g. drug eluting stents (DES)) that reduced substantially the rates of restenosis to less than 10%, [3, 4] the rates of late in-stent thrombosis, a devastating complication in terms of morbidity and mortality, are higher with DES compared to bare metal stents. [5] Recent reports suggest that the risk of late-stent thrombosis appears to be steadily present over time, [6, 7] and, indeed, there have been reports of these events occurring 4.5 to 5 years after DES implantation. [8, 9] Thus, late in-stent thrombosis remains a major problem in clinical practice. [10, 11] DES contain antiproliferative agents (e.g. rapamycin or paclitaxel), which target vascular smooth muscle cells (VSMCs) and inhibit their migration and proliferation to the site of injury following stent deployment, thus ultimately preventing neointimal formation and restenosis. However, DES also interfere with re-endothelialization of the stent struts, which currently is thought to play a central role in the pathogenesis of very late (>12 months)
in-stent thrombosis observed with DES. [12, 13] With this in mind, the search for compounds capable of selectively inhibiting migration and proliferation of VSMCs, but sparing endothelial cell (EC) migration and proliferation, for use in DES is of utmost importance.
During restenosis following stent deployment, VSMCs undergo significant changes in morphology and function exhibiting a "synthetic" or "dedifferentiated" phenotype, whereby these cells synthesize components of the extracellular matrix and exhibit characteristics similar to immature cells found in blood vessels during development. [14, 15] In the intact vessel wall, however, VSMCs exhibit a "differentiated" or contractile phenotype characterized by a spindle shape and increased expression of contractile proteins, which correlates with increased contractile ability.
[15]
Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear hormonereceptor superfamily. [16] PPARγ expression has been shown to increase in the intima in response to injury. [17] It has been proposed that increased activity of PPARγ in blood vessels is important for limiting neointimal formation by enhancing the differentiation of VSMCs and thereby reducing their migratory ability. [18] Previous studies from our laboratory, and others, have demonstrated that ibuprofen, as well as certain other non-steroidal anti-inflammatory drugs (NSAIDs), reduces VSMC proliferation in a dose-and cell cycle-dependent manner. [19, 20] In addition, several lines of evidence indicate that NSAIDs, including ibuprofen, have the ability to activate PPARγ receptors in several cell types and tissues. [21] [22] [23] Here, we confirm that ibuprofen inhibits proliferation and report for the first time that ibuprofen inhibits migration of human coronary artery smooth muscle cells (HCASMCs), and that this correlates with the induction of a differentiated phenotype in these cells. We also report that at least some of the effects of ibuprofen on HCASMCs are mediated through PPARγ. More importantly, we also show for the first time that the effect of ibuprofen is cell type specific as it does not affect migration and proliferation of endothelial cells. Taken together, our results suggest that ibuprofen could be a potential molecule for incorporation into DES which may prevent restenosis without interfering with the process of re-endothelialization, thus having the potential of preventing other complications stent implantation.
Materials and Methods

Antibodies and reagents
Antibodies raised against SMα-actin (ab5694), SM22α (ab14106), GAPDH (ab8245), β-actin (ab6276) and Lamin A (ab8980) were from Abcam (UK); antibody raised against PPARγ (sc-7273) was from Santa Cruz Biotechnology (USA), antibody raised against ATF-2 (9226) was from Cell Signalling Technology (USA). Alexa Fluor 488 goat anti-mouse (A-11001), Alexa
Fluor 594 phalloidin (A12381) and prolong® Gold anti-fade reagent with DAPI (P36935)
were from Life Technologies (UK). Most chemicals, including ibuprofen and troglitazone were obtained from Sigma (UK); Mitomycin C was from Calbiochem (UK); GW9662 was obtained from Biomol (UK); PGF2α was from Merck Chemicals (UK). Tissue culture plates and dishes were from Thermo Fisher Nunc.
Cell culture
Primary human coronary artery smooth muscle cells (HCASMCs) and primary human coronary artery endothelial cells (HCAECs) were purchased from PromoCell (GmbH, Heidelberg, Germany), and cultured according to manufacturer's instructions using PromoCell's smooth muscle cell growth medium 2 (C-22062) or endothelial cell growth medium MV2 (C-22022), both of which contains 5% serum without antibiotics or antifungal agents. Passaging was according to the manufacturer's instructions using DetachKit, also from PromoCell. Primary human pulmonary microvascular endothelial cells (HPMECs) were purchased from PromoCell (GmbH, Heidelberg, Germany). Growth media for HPMECs was prepared to give a final concentration of 20% (v/v) serum, and a concentration of 50μg/mL endothelial cell growth supplement in M199 with GlutaMAX™ medium.
For all experiments, cells were used between passages 3-5 and were cultured replacing with the same fresh growth medium described above. For proliferation assays, HCASMCs 
Proliferation analysis
Following an initial 24 h incubation, media was replaced without agonists (vehicle controls) or treated with different doses of ibuprofen. After a further 72 h, direct cell counting was performed by trypan blue exclusion. [20] Wound healing assay
Migration was investigated using a wound healing "scratch" assay as described before, [24, 25] with minor modifications. Briefly, 24 h after plating both HCASMCs and HCAECs at the desired cell density, medium was replaced in the absence (control) or presence of different concentrations of ibuprofen or troglitazone, and in some instances with the selective PPARγ inhibitors, GW9662 or PGF2α. [26] [27] [28] Mitomycin C, was added one hour before scratching at a concentration of 0.5 µg/ml. This concentration of mitomycin C completely blocks proliferation of HCASMCs within 1 h of administration (data not shown). A scratch in the cell monolayer was then generated with a sterile 200 µl micropipette tip and images of the gap were captured immediately (time 0 h) and repeated at 24 h (HCASMCs) or 10 h (HCAECs) using a phase contrast microscope with an attached ProgRes SpeedXT core 5 digital camera (Jenoptik Systems GmbH) with ProgRes CapturePro 2.8.8. The extent of closure of the gap (HCAECs) or migrated cell number (HCASMCs) was analysed using ImageJ (NIH, Bethesda).
Time lapse videomicroscopy
Time lapse video microscopy was used for in vitro real time analysis of HCASMCs and HCAECs migration, as described before, [29] with minor modifications. 1200 Japan (NIS-elements AR software). All microscopy stages were performed in a controlled environment (37°C and 5% CO 2 ). The distance that a particular cell had migrated within 48 h was analysed using ImageJ software (NIH, Bethesda).
Immunoblotting
Whole cell extracts were prepared as described previously with minor modifications. [20] Briefly, HCASMCs or HCAECs were washed gently in ice cold PBS and scraped into 150 µl Nuclear extracts were prepared as described previously, with minor modifications. [30, 31] Briefly, HCASMCs or HCAECs were washed gently in ice cold PBS and scraped into 150 µl ice cold nuclear buffer A [10 mM HEPES pH 7.9, 10 mM KCl, 1. (20 µg) were separated by SDS-polyacrylamide gel electrophoresis using 10% (w/v) resolving gels and 6% (w/v) stacking gels, and transferred to nitrocellulose as described previously. [31] Nonspecific binding sites were blocked with 5% in TBS-T. Bands were detected using enhanced chemiluminescence (ECL) Prime (GE Healthcare) and an ImageQuant LAS4000 mini digital imager (GE Healthcare). ImageQuant 8.1 (GE Healthcare) software was used for densitometric analysis.
Immunocytochemistry
HCASMCs were exposed to 500 µM ibuprofen for 72 h, then washed with PBS and fixed in 4% (v/v) formaldehyde (10 min at room temperature). Following permeabilization with 0.1%
Triton X-100 in PBS (10 min at room temperature) and incubation with 1% (w/v) BSA in PBS containing 0.1% Triton X-100 (20 min at room temperature) to block non-specific antibody binding, immunocytochemistry was performed as described previously with minor modifications. [31] Briefly, cover slides were incubated with mouse monoclonal primary antibodies against β-actin 
Statistical Analysis
Statistical analysis was performed with Graphpad Prism 5.0. The data are presented as mean ± SEM, and significance of results was determined by one-way ANOVA with Dunnet's or Tukey's post test, and, where appropriate, a paired two-tailed student t test. The results were considered significant when p< 0.05.
Results
Proliferation and migration of HCASMCs is inhibited by ibuprofen in a dose dependent manner
Proliferation and migration of VSMCs are key elements in the pathophysiology of restenosis post-stent implantation. [33] Previous studies from our laboratory demonstrated that A10 rat VSMC proliferation was inhibited by several NSAIDs in a dose-dependent manner. [20] Here, we first evaluated whether proliferation of human primary HCASMCs is similarly affected by ibuprofen. Treatment with different concentrations of ibuprofen did, indeed, cause an inhibitory effect on the proliferation of HCASMCs in a dose-dependent manner. Thus, whilst 100 µM ibuprofen had no significant effect, concentrations above 250 µM progressively inhibited proliferation of HCASMCs, with an IC 50 of 680±120 µM ( Figure 1A ).
We then performed in vitro studies to evaluate the effects of ibuprofen on the migration of HCASMCs. Using a wound healing "scratch" assay (a well validated method for evaluating migration of cells in vitro), [25] we first observed that HCASMCs migrate individually rather 
Ibuprofen induces a phenotypic switch in HCASMCs
Previous studies have shown that, during culture in the presence of serum, VSMCs become de-differentiated, adopting an amoeboid shape and exhibiting increased synthesis of components of the extracellular matrix, thus the term "synthetic" that is commonly used to describe this phenotype. [34] Associated with this change in phenotype, de-differentiated VSMCs also show a reduced expression of contractile proteins, including SMα-actin, SM22α
and F-actin. [33, 34] In contrast, serum starvation or treatment with rapamycin, induces differentiation of VSMCs with a characteristic spindle shape and increased expression of contractile proteins, giving rise to the commonly used term, "contractile" phenotype [33] [34] [35] Importantly, during vascular damage (e.g. stent deployment), VSMCs migrate and proliferate to the site of injury, and this correlates with a change from a contractile towards a synthetic phenotype.
Given the effects of ibuprofen on the proliferation and migration of HCASMCs, we tested the possibility that these effects correlate with a change in the de-differentiation state of these cells. Therefore, we investigated the morphology of HCASMCs using immunocytochemistry.
Treatment with 500µM ibuprofen for 72 h induced a change in morphology, from an amoeboid into a spindle shape ( Figure 3A) . Characteristically, the observed change in cell surface area induced by ibuprofen mainly affects the width of the treated cell whereas the length of the cell remains unchanged ( Figure 3B-3D ).
We next investigated whether the changes in morphology induced by ibuprofen correlated with changes in expression of markers of the differentiated state. [34] HCASMCs cultured in the presence of serum, were either untreated (vehicle controls) or exposed to ibuprofen 500 µM, and the protein levels of SMα-actin and SM22α were then assessed by immunoblotting analysis. As shown in Figure 4A -C, the protein levels of SMα-actin and SM22α were upregulated following treatment with ibuprofen for 72 hours. When we analyzed the myofilament density of HCASMC, it revealed that treatment with ibuprofen increased the phalloidin staining intensity of F-actin, another marker of differentiation of VSMCs, [34] as compared with untreated, vehicle controls ( Figure 4D ), further supporting the possibility that ibuprofen induces a switch from a synthetic to a contractile phenotype in HCASMCs.
The effects of ibuprofen on HCASMCs are partially mediated by PPARγ
Many effects of NSAIDs are mediated via cyclooxygenase (COX)-independent mechanisms; [36] indeed, previous studies have demonstrated that ibuprofen and other
NSAIDs are agonists of PPARγ. [21] [22] [23] On the other hand, the major metabolite of arachidonic acid via COX in VSMCs is PGF2α. [37] Interestingly, PGF2α is a selective antagonist of PPARγ. [26, 27] To study the molecular mechanisms of the effects of ibuprofen in HCASMCs,
we evaluated whether the selective natural antagonist of PPARγ, PGF2α, [26, 27] or the selective synthetic antagonist, GW9662, [28] could prevent the effects of ibuprofen in
HCASMCs. We then explored whether the effects of ibuprofen on morphology and expression of markers of differentiation in HCASMCs were also mediated via PPARγ. As shown in Figures   3A and 3B, cell surface area in HCASMCs treated with ibuprofen in combination with GW9662 (3 µM) was similar to that of medium alone-treated control cells, and was significantly higher than those treated with ibuprofen alone, suggesting that PPARγ does, indeed, play a role in the phenotype switch induced by ibuprofen. However, whilst GW9662 significantly inhibits the effects on morphology induced by ibuprofen, they do not return to levels seen in untreated, control cells ( Figures 3A and 3B ), suggesting that other pathways might also be involved in mediating these morphological effects. Indeed, troglitazone, a selective PPARγ agonist, induces changes in the morphology of HCASMCs but these are qualitatively different to those induced by ibuprofen ( Figure 3A) . Thus, whilst ibuprofen induces a change in morphology resembling the characteristic spindle shape of differentiated VSMCs as described previously, [34, 35] troglitazone affects both cell width and cell length in HCASMCs as opposed to ibuprofen that mainly affects cell width without affecting cell length ( Figures 3A-3D ). Finally, we evaluated the expression of protein markers of VSMC differentiation. Significantly, whilst ibuprofen induced expression of both SMα-actin and SM22α ( Figures 4A-4C , 6A-6C), incubation with PGF2α did not significantly inhibit these effects. In fact, SM22α expression levels in the presence of PGF2α alone, or in combination with ibuprofen, did not differ; the effect of troglitazone was comparable to that of ibuprofen ( Figures 6A and 6C ). In contrast, whereas PGF2α had a trend to inhibit the effects of ibuprofen on SMα-actin expression, this was not significant, and troglitazone failed to induce expression of this protein above control levels ( Figures 6A and 6B ).
Ibuprofen does not affect migration and proliferation of endothelial cells
Taken together, our results suggest that ibuprofen inhibits proliferation and migration of HCASMCs and this is partially mediated by the PPARγ pathway. In clinical practice, the ideal DES would prevent restenosis and also late and very late in-stent thrombosis. It has been suggested that the currently available DES target VSMC migration and proliferation, but in doing so they also prevent re-endothelialisation of the stent struts, with the risk of very late in-stent thrombosis steadily occurring over time, [6, 7] indicating that complete healing of the vessel wall is never achieved. Novel DES that prevent migration and proliferation of VSMCs whilst permitting the migration and proliferation of ECs, and thus allowing re-endothelialization, could offer a significant advantage for DES stent therapy. Therefore, we performed "scratch" wound assays and time-lapse videomicroscopy analysis to evaluate the effects of ibuprofen on migration of HCAECs.
As shown in Figure 7A , ibuprofen at all concentrations tested (100 -1000 µM) does not significantly affect migration of HCAECs as measured via a "scratch" wound assay.
Similarly, ibuprofen at a concentration of 750µM, which potently inhibits migration of HCASMCs ( Figure 1B We next compared the expression levels of PPARγ in both HCASMCs and HCAECs. First, we were able to determine that PPARγ, as a nuclear receptor protein, was present mainly in the nuclear fractions of both cell types ( Figure 8A ). To verify the loading of nuclear fractions, membranes were probed with ATF2 antibody, and, as shown in Figures 8B and 8C , densitometric analysis showed that PPARγ was more abundant in HCASMCs than in HCAECs when levels were normalized to the loading control, ATF2 ( Figures 8B and 8C ).
Interestingly the protein expressed in both cell types had a molecular mass of ≈53 kDa (see Discussion).
Discussion
Restenosis post stent implantation is a complex pathophysiological process, which involves proliferation and migration of VSMCs to the site of injury (e.g. following balloon angioplasty and stent deployment) and a change in VSMCs towards a synthetic/proliferative phenotype. [33] Indeed, the restenotic vessel wall is mostly composed of extracellular matrix proteins synthetized by dedifferentiated proliferative VSMCs. [14] Recent advances in stent technology, including DES containing antiproliferative agents (e.g. rapamycin and paclitaxel)
have reduced significantly the rate of restenosis to less than 10% over the past decade. [3, 4] However, despite the success of DES in reducing restenosis rates, there is a constant threat of late and very late in-stent thrombosis, particularly following abrupt discontinuation of dual antiplatelet therapy. [5] Several factors appear to be implicated in the biology of late in-stent thrombosis, but most evidence suggests it is the lack of selectivity of DES targeting not only VSMCs but also endothelial cells, thus interfering with the process of re-endothelialisation and vessel wall repair. [12, 13] Thus, novel compounds capable of selectively targeting VSMCs migration and proliferation without interfering with the process of re-endothelialization are urgently needed. Indeed, the ideal stent should be capable of maintaining low rates of restenosis, reducing the risk of early or late in stent thrombosis, and promoting vessel wall healing by modulating the inflammatory response within the vessel wall. [15, 38] Several second generation DES, containing everolimus, or zotarolimus, share the molecular mechanisms of their predecessor, sirolimus (rapamycin), and therefore target VSMCs as well as endothelial cells. Whilst recent clinical trials suggest improved outcomes compared to first generation DES up to 2 years of follow up, [39] their performance in terms of late complications such as late and very late (>12 months) stent thrombosis remain to be determined.
We, and others, have previously shown that certain NSAIDs, including the propionic acid derivative, ibuprofen, are capable of reducing rat VSMCs proliferation in a dose-and cell cycle-dependent manner. [19, 20] Here, we studied the ability of ibuprofen to inhibit proliferation and migration of HCASMCs. First, we demonstrated that ibuprofen was able to inhibit both proliferation and migration of HCASMCs in a dose-dependent manner. Of note, the concentration required to inhibit proliferation of HCASMCs (IC 50 680±120 µM) is similar to the dose that inhibited A10 rat VSMCs proliferation in our previous study (IC 50 646 µM). [20] A similar concentration range is required for inhibition of HCASMC migration (IC 50 410±60 µM)
as demonstrated by wound healing "scratch" assay and also by time lapse video microscopy. Interestingly, we also found that the effects of ibuprofen on HCASMC migration and proliferation correlated with the induction of a phenotypic switch on HCASMCs towards a differentiated, contractile state, characterized by a spindle shape morphology and increased expression of known contractile protein markers of differentiation. [33] [34] [35] Accumulating evidence indicates that NSAIDs have pleiotropic effects in many cell types, and therefore may have a therapeutic role in several conditions including prevention and treatment of certain types of cancer, [36] and in prevention and treatment of neurodegenerative diseases, such as Alzheimer disease. [22] It has been demonstrated previously that Ibuprofen, as well as other NSAIDs, activate PPARγ in several cell types. [21, 40] Indeed, Ibuprofen at the dose range used in our studies, has been shown to activate the PPARγ pathway. [23, 41] In addition, ibuprofen reduces glial inflammation via a PPARγ-dependent mechanism, thus explaining the beneficial effects of ibuprofen and other NSAIDs in Alzheimer's disease. [23, 42] The report of Weber et al (2000) , suggests that the effects of ibuprofen on VSMCs proliferation are COX-independent. [19] Significantly, PPARγ appears to be protective in the cardiovascular system, and has important regulatory roles in vascular biology. [43] Our data indicate that ibuprofen-induced inhibition of HCASMC proliferation appears to be mediated primarily by the PPARγ pathway, since pre-incubation with the selective PPARγ antagonists, PGF2α and GW9662, almost completely restored the proliferative ability of HCASMCs to control levels. To our knowledge, only few studies have aimed to elucidate the mechanisms whereby NSAIDs inhibit VSMCs proliferation. One study found that several NSAIDs, including ibuprofen, inhibit A10 VSMCs proliferation via inhibition of store operated Ca2+ entry (SOCE) channels, an important Ca2+ entry pathway involved in cell proliferation. [44] Another study showed that aspirin inhibited VSMCs proliferation by inducing phosphorylation of AMP-activated protein kinase. [45] The precise mechanisms whereby ibuprofen via activation of PPARγ inhibit proliferation in VSMCs remain to be elucidated; further studies are needed to clarify this. Several agonists of PPARγ have been described including thiazolidinediones (e.g. ciglitazone, troglitazone, pioglitazone, rosiglitazone), and natural ligands including prostanoids, such as 15d-PGJ2, as well as n3-polyunsaturated fatty acids. [43] These PPARγ agonists appear to inhibit VSMCs proliferation via downstream mechanisms that include, inhibiting the expression of the transcription factor c-fos, [46, 47] blockade of Angiotensin-II induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2), [18, 48, 49] and suppression of cell cycle signaling through decreased phosphorylation of the retinoblastoma protein (Rb), [50] a mediator of G1/S progression, and prevention of mitogen induced degradation of p27(Kip1), [50] an inhibitor of cdk and Rb phosphorylation. Since the effect of PPARγ inhibitors did not completely abrogate the migratory response, other pathways could be involved in this response in addition to PPARγ. We speculate that one such pathway could be COX2. Indeed, one of the main metabolites of arachidonic acid in VSMCs is PGF2α, [37] and this metabolite is a natural selective antagonist of PPARγ. [26, 27] Similarly, in vivo studies have shown that there is increased expression and activity of COX2 in the intima following vascular injury. [17, 51] Furthermore, the synthesis of PGF2α via COX activity is increased by PDGF, [52, 53] an important regulator of the differentiation state of VSMCs, which induces dedifferentiation of VSMCs towards a synthetic phenotype and promotes their migration and proliferation. [54] [55] [56] In agreement with these observations, our preliminary data using the wound healing "scratch" assay, indicate that celecoxib, a COX2
selective inhibitor, at doses that are non-toxic to the cells (6.25 -25 µg), prevents migration of rat A10 VSMCs whilst sparing HCAECs migration (unpublished observations).
Of note, our data also indicate that migration and proliferation of ECs is not affected by ibuprofen, suggesting that the effect of ibuprofen is cell-type specific. This is an important novel finding form our study and to our knowledge this is the first evidence indicating that a molecular compound such as ibuprofen has the ability to selectively inhibit VSMCs belong to a nuclear receptor superfamily, of which two isoforms, PPARγ1 (53 kDa) and PPARγ2 (57 kDa), are formed from the same gene by alternative mRNA splicing. [57, 58] Our results indicate that a single protein band of approximate 53 kDa is detectable in nuclear extracts of both HCASMCs and HCAECs (Figure 8 ), likely corresponding to the PPARγ1 isoform. This is in agreement with previous studies suggesting that only PPARγ1 is expressed in VSMCs and endothelial cells of different species and tissues. [59, 60] We also observed that the relative expression levels of PPARγ appear to be higher in HCASMCs compared to HCAECs, and this could partly explain the sensitivity of HCASMCs to the effects of ibuprofen.
Drugs currently used in DES including sirolimus, paclitaxel and zotarolimus inhibit proliferation of VSMCs in nano molar concentrations. [61, 62] Thus, a potential limitation of our study is that IC 50 concentrations of ibuprofen for migration and proliferation appear to be very high which may difficult the feasibility of using ibuprofen in a DES.
Taken together, our results suggest that the in vitro effects of ibuprofen on migration and proliferation, coupled with the induction of a phenotype switch towards a differentiated state whilst sparing migration of HCAECs, could be exploited by the incorporation of ibuprofen into a DES to prevent restenosis post stent implantation and potentially reduce other complications of DES stent implantation by not interfering with migration and proliferation of ECs. Whether our in vitro observations could be translated clinically into a DES of increased performance remains to be demonstrated. Future studies will aim to evaluate the feasibility of ibuprofen-containing DES in in vivo animal models of vascular injury and restenosis.
Conclusion
In conclusion, this study demonstrates for the first time that ibuprofen induces a phenotypic 
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